Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Celltrion Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Celltrion Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Celltrion Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Celltrion Enters into Co- Development Agreement with Yonsei University 12
Celltrion Enters into Development Agreement with Emory University 13
Nippon Kayaku Enters into Agreement with Celltrion Healthcare 14
Teva Pharma Enters into Distribution Agreement with Celltrion 15
Licensing Agreements 16
Hikma Pharma Enters into Licensing Agreement with Celltrion and Celltrion Healthcare 16
Mundipharma Enters into Licensing Agreement with Celltrion Healthcare Hungary for Remsima 17
Equity Offering 19
Celltrion Healthcare Raises USD900.7 Million in IPO 19
Debt Offering 20
Celltrion Pharm Raises USD27.1 Million in Public Offering of 1.5% Bonds Due 2019 20
Celltrion Pharm Raises USD46.3 Million in Public Offering of 1.5% Bonds Due 2020 21
Celltrion Pharm Raises USD9.2 Million in Public Offering of 1.5% Bonds Due 2019 22
Celltrion Pharm Raises USD56.6 Million in Public Offering of 1.5% Bonds Due 2018 23
Celltrion Raises USD300 Million Public Offering of 2.75% Bonds Due 2018 24
Acquisition 25
Temasek Acquires Additional Stake In Celltrion 25
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 26
Celltrion Inc – Key Competitors 28
Celltrion Inc – Key Employees 29
Celltrion Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Legal and Regulatory 31
Sep 18, 2018: Celltrion receives EIR from the FDA 31
Product News 32
05/23/2017: Miraca Life Sciences Again Expands Therapeutic Drug Monitoring with Addition of First Biosimilar Inflectra 32
05/18/2017: Celltrion Healthcare Hungary Receives CHMP Positive Opinion for Blitzima (rituximab) 33
02/22/2017: Mundipharma to launch Truxima (rituximab), the first biosimilar monoclonal antibody for the treatment of cancer, in seven European markets 34
02/17/2017: New Data in Crohn’s Disease Patients Shows Similar Efficacy and Safety Profiles for INFLECTRA and REMICADE 35
02/17/2017: Celltrion Healthcare Releases Positive Results from Pivotal Study in Crohns Disease 36
Product Approvals 37
May 30, 2018: Celltrion Completes Resubmission for Biosimilar Candidate to FDA for Review 37
Apr 06, 2018: Celltrion Receives CRL from the U.S. FDA for rituximab biosimilar 38
Jun 29, 2017: Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Rituxan (rituximab) 39
Clinical Trials 40
Dec 11, 2017: Top UK university hospital unveils data that support the use of rapid infusion for Truxima (CT-P10, biosimilar rituximab) in patients with advanced-stage follicular lymphoma 40
Nov 05, 2017: Celltrion Healthcare Presents Phase III Switching Data Supporting the Long-Term Efficacy and Safety of Truxima (CT-P10, Biosimilar Rituximab) in Rheumatoid Arthritis Patients 41
Oct 29, 2017: One Year Maintenance And Switching Data In Patients With Crohn’s Disease Support The Use Of Inflectra (Infliximab CT-P13) In IBD 42
Jun 14, 2017: Celltrion Healthcare showcases data supporting the efficacy and safety of Truxima (CT-P10, biosimilar rituximab) in advanced follicular lymphoma and rheumatoid arthritis 43
May 12, 2017: Celltrion Healthcare: Lancet Publishes Full Data-Set from Influential NOR-SWITCH Study 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45
Celltrion Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Celltrion Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Celltrion Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Celltrion Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Celltrion Enters into Co- Development Agreement with Yonsei University 12
Celltrion Enters into Development Agreement with Emory University 13
Nippon Kayaku Enters into Agreement with Celltrion Healthcare 14
Teva Pharma Enters into Distribution Agreement with Celltrion 15
Hikma Pharma Enters into Licensing Agreement with Celltrion and Celltrion Healthcare 16
Mundipharma Enters into Licensing Agreement with Celltrion Healthcare Hungary for Remsima 17
Celltrion Healthcare Raises USD900.7 Million in IPO 19
Celltrion Pharm Raises USD27.1 Million in Public Offering of 1.5% Bonds Due 2019 20
Celltrion Pharm Raises USD46.3 Million in Public Offering of 1.5% Bonds Due 2020 21
Celltrion Pharm Raises USD9.2 Million in Public Offering of 1.5% Bonds Due 2019 22
Celltrion Pharm Raises USD56.6 Million in Public Offering of 1.5% Bonds Due 2018 23
Celltrion Raises USD300 Million Public Offering of 2.75% Bonds Due 2018 24
Temasek Acquires Additional Stake In Celltrion 25
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 26
Celltrion Inc, Key Competitors 28
Celltrion Inc, Key Employees 29
Celltrion Inc, Subsidiaries 30
List of Figures
Celltrion Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Celltrion Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9